FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Chapman Christopher C JR			2. Issuer Name and Ticker or Trading Symbol <u>MyMD Pharmaceuticals, Inc.</u> [MYMD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(First) STREET, SUITE 601	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/04/2023	x	Director Officer (give title below) President, Chief Med	10% Owner Other (specify below)			
(Street) BALTIMORE	MD	21205	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	idual or Joint/Group Filing (Ch Form filed by One Reporting Form filed by More than On	g Person			
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	ict, instruc	tion or written plan that is intended	d to satisfy the			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (In 8)		Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) (Instr. 4)	
	Code V Amount (A) or (D)		Price	· Transaction(s) (Instr. 3 and 4)	(instr. 4)					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$1.55	04/04/2023		A		750,000		(1)	04/04/2028	Common Stock	750,000	\$ <u>0</u>	750,000	D	

Explanation of Responses:

1. The stock options vest as follows: (i) 250,000 on the date of grant; (ii) 250,000 on the first anniversary of the date of grant; and (iii) 250,000 on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

/s/	Chris	Cha	pmai	n	

04/05/2023 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL